Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease

Curr Hypertens Rep. 2001 Dec;3 Suppl 2:S31-3. doi: 10.1007/s11906-001-0105-8.

Abstract

In both the natriuretic peptide and renin-angiotensin systems, peptidases play an important role in the inactivation or activation of the system. Angiotensin-converting enzyme is responsible for the conversion of angiotensin I to angiotensin II, while neutral endopeptidase is one of the pathways involved in the degradation of the natriuretic peptides. The vasopeptidase inhibitors, which simultaneously inhibit neutral endopeptidase and angiotensin-converting enzyme, appear to offer distinct therapeutic advantages in treating hypertension, heart failure, and endothelial dysfunction.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Cardiotonic Agents / pharmacology*
  • Endothelium, Vascular / drug effects*
  • Heart / drug effects
  • Heart Failure / drug therapy*
  • Humans
  • Hypertension / drug therapy*
  • Kidney / drug effects
  • Kidney Failure, Chronic / drug therapy*
  • Kidney Failure, Chronic / etiology
  • Neprilysin / antagonists & inhibitors*
  • Renin-Angiotensin System / drug effects

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Cardiotonic Agents
  • Neprilysin